Tags

Type your tag names separated by a space and hit enter

Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
Cardiol J 2019; 26(2):147-156CJ

Abstract

BACKGROUND

Geographical differences in patient characteristics, management and outcomes in heart failure (HF) trials are well recognized. The aim of this study was to assess the consistency of the treat- ment effect of coenzyme Q10 (CoQ10) in the European sub-population of Q-SYMBIO, a randomized double-blind multinational trial of treatment with CoQ10, in addition to standard therapy in chronic HF.

METHODS

Patients with moderate to severe HF were randomized to CoQ10 300 mg daily or placebo in addition to standard therapy. At 3 months the primary short-term endpoints were changes in New York Heart Association (NYHA) functional classification, 6-min walk test, and levels of N-terminal pro-B type natriuretic peptide. At 2 years the primary long-term endpoint was major adverse cardiovascular events (MACE).

RESULTS

There were no significant changes in short-term endpoints. The primary long-term endpoint of MACE was reached by significantly fewer patients in the CoQ10 group (n = 10, 9%) compared to the placebo group (n = 33, 27%, p = 0.001). The following secondary endpoints were significantly improved in the CoQ10 group compared with the placebo group: all-cause and cardiovascular mortality, NYHA classification and left ventricular ejection fraction (LVEF). In the European sub-population, when compared to the whole group, there was greater adherence to guideline directed therapy and similar results for short- and long-term endpoints. A new finding revealed a significant improvement in LVEF.

CONCLUSIONS

The therapeutic efficacy of CoQ10 demonstrated in the Q-SYMBIO study was confirmed in the European sub-population in terms of safely reducing MACE, all-cause mortality, cardiovascular mortality, hospitalization and improvement of symptoms.

Authors+Show Affiliations

annelou.mortensen@gmail.com.Faculty of Health, Arts and Design, Swinburne University of Technology, Melbourne, Australia. Baker Heart and Diabetes Institute, Melbourne, Australia.1st Department of Cardiology, Medical University of Warsaw, Poland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30835327

Citation

Mortensen, Anne Louise, et al. "Effect of Coenzyme Q10 in Europeans With Chronic Heart Failure: a Sub-group Analysis of the Q-SYMBIO Randomized Double-blind Trial." Cardiology Journal, vol. 26, no. 2, 2019, pp. 147-156.
Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiol J. 2019;26(2):147-156.
Mortensen, A. L., Rosenfeldt, F., & Filipiak, K. J. (2019). Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal, 26(2), pp. 147-156. doi:10.5603/CJ.a2019.0022.
Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of Coenzyme Q10 in Europeans With Chronic Heart Failure: a Sub-group Analysis of the Q-SYMBIO Randomized Double-blind Trial. Cardiol J. 2019;26(2):147-156. PubMed PMID: 30835327.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. AU - Mortensen,Anne Louise, AU - Rosenfeldt,Franklin, AU - Filipiak,Krzysztof J, Y1 - 2019/03/05/ PY - 2019/01/31/received PY - 2019/02/05/accepted PY - 2019/3/6/pubmed PY - 2019/3/6/medline PY - 2019/3/6/entrez KW - chronic heart failure KW - coenzyme CoQ10 KW - hospitalization KW - major adverse cardiovascular events KW - mortality KW - randomized controlled trial KW - ubiquinone SP - 147 EP - 156 JF - Cardiology journal JO - Cardiol J VL - 26 IS - 2 N2 - BACKGROUND: Geographical differences in patient characteristics, management and outcomes in heart failure (HF) trials are well recognized. The aim of this study was to assess the consistency of the treat- ment effect of coenzyme Q10 (CoQ10) in the European sub-population of Q-SYMBIO, a randomized double-blind multinational trial of treatment with CoQ10, in addition to standard therapy in chronic HF. METHODS: Patients with moderate to severe HF were randomized to CoQ10 300 mg daily or placebo in addition to standard therapy. At 3 months the primary short-term endpoints were changes in New York Heart Association (NYHA) functional classification, 6-min walk test, and levels of N-terminal pro-B type natriuretic peptide. At 2 years the primary long-term endpoint was major adverse cardiovascular events (MACE). RESULTS: There were no significant changes in short-term endpoints. The primary long-term endpoint of MACE was reached by significantly fewer patients in the CoQ10 group (n = 10, 9%) compared to the placebo group (n = 33, 27%, p = 0.001). The following secondary endpoints were significantly improved in the CoQ10 group compared with the placebo group: all-cause and cardiovascular mortality, NYHA classification and left ventricular ejection fraction (LVEF). In the European sub-population, when compared to the whole group, there was greater adherence to guideline directed therapy and similar results for short- and long-term endpoints. A new finding revealed a significant improvement in LVEF. CONCLUSIONS: The therapeutic efficacy of CoQ10 demonstrated in the Q-SYMBIO study was confirmed in the European sub-population in terms of safely reducing MACE, all-cause mortality, cardiovascular mortality, hospitalization and improvement of symptoms. SN - 1897-5593 UR - https://www.unboundmedicine.com/medline/citation/30835327/Effect_of_coenzyme_Q10_in_Europeans_with_chronic_heart_failure:_A_sub_group_analysis_of_the_Q_SYMBIO_randomized_double_blind_trial_ L2 - https://journals.viamedica.pl/cardiology_journal/article/view/62920 DB - PRIME DP - Unbound Medicine ER -